Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aptevo Therapeutics Inc (NQ: APVO )

0.4193 +0.0013 (+0.31%)
Streaming Delayed Price Updated: 9:44 AM EDT, Aug 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aptevo Therapeutics Inc

< Previous 1 2 Next >
Aptevo Therapeutics Announces Closing of $2.75 Million Offering
Via ACCESSWIRE
Aptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market Under Nasdaq Rules
Via ACCESSWIRE
Aptevo Participating in the BIO International Convention
Via ACCESSWIRE
Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MA
Via ACCESSWIRE
Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides a Business Update
Via ACCESSWIRE
Aptevo Therapeutics Reports 2023 Financial Results and Provides a Business Update
Via ACCESSWIRE
Aptevo Therapeutics Reports 3Q23 Financial Results and Provides a Business Update
Via ACCESSWIRE
Aptevo Therapeutics Reports 2Q23 Financial Results and Provides a Business Update
Via ACCESSWIRE
Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering
Via ACCESSWIRE
Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering
Via ACCESSWIRE
Aptevo Therapeutics Provides Pipeline Update
Via ACCESSWIRE
Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference
Via ACCESSWIRE
Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4
Via ACCESSWIRE
Aptevo Therapeutics Reports 1Q23 Financial Results and Provides Business Update
Via ACCESSWIRE
Aptevo Therapeutics Reports 2022 Financial Results and Provides Business Update
Via ACCESSWIRE
Aptevo Therapeutics Raises $9.6 Million in Non-Dilutive Funding
Via ACCESSWIRE
Aptevo Therapeutics Announces 1-for 44 Reverse Stock Split As Part of Nasdaq Compliance Plan
Via ACCESSWIRE
Aptevo to Present at Bio-Europe Conference
Via ACCESSWIRE
Aptevo Therapeutics Inc. Announces Closing of Previously Announced $5 Million Public Offering
Via ACCESSWIRE
Aptevo Therapeutics Inc. Announces Pricing of $5 Million Public Offering
Via ACCESSWIRE
Alligator Bioscience & Aptevo Therapeutics Announce Dosing of First Patient with ALG.APV-527 in Phase 1 Clinical Trial
Via ACCESSWIRE
Aptevo Therapeutics Files Provisional Patent for Fifth Bispecific Antibody APVO711, Intended for the Treatment of Solid Tumors
Via ACCESSWIRE
Aptevo Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
Via ACCESSWIRE
Aptevo Announces Positive Duration of Remission Data from Phase 1b Expansion Trial Evaluating the Bispecific APVO436 for AML
Via ACCESSWIRE
100% Clinical Benefit Rate Achieved in Phase 1b Trial Evaluating APVO436 in Combination with Venetoclax and Azacitidine for Venetoclax Treatment Naïve Patients with Acute Myeloid Leukemia (AML)
Via ACCESSWIRE
Alligator Bioscience & Aptevo Therapeutics Announce Publication Highlighting ALG.APV-527 Preclinical Data in Peer-Reviewed Journal Molecular Cancer Therapeutics
Via ACCESSWIRE
Aptevo Therapeutics Announces Poster Presentation at the 64th American Society of Hematology Annual Meeting and Exposition
Via ACCESSWIRE
Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a "May Proceed" Notification for the ALG.APV-527 IND
Via ACCESSWIRE
Aptevo Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
Via ACCESSWIRE
Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid Leukemia
Cohort 1 Combination Therapy Arm Shows 36% Remission Rate Among Response-evaluable Patients Treated to Date 
From Aptevo Therapeutics
Via AccessWire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.